Treatment for Migraines With an Implantable Device

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: February 1, 2006
Last updated: December 3, 2015
Last verified: December 2015
The purpose of this study is to evaluate the safety and effectiveness of an implantable device for difficult to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative therapies are needed.

Condition Intervention Phase
Device: Precision
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Precision Implantable Stimulator for Migraine (PRISM) Study- Occipital Nerve Stimulation (ONS) for Migraine

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Migraine Frequency at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change from baseline in migraine days/month at 12 weeks

  • Frequency of Adverse Event. [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
    Cumulative frequency of adverse events an events per subject from randomization to 26 weeks

Enrollment: 179
Study Start Date: February 2006
Estimated Study Completion Date: December 2016
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Stimulation on
Device: Precision
Implantable neurostimulator
Sham Comparator: 2
Sham Stimulation up to 12 weeks post-activation. Actual Stimulation from 12 weeks post-activation on.
Device: Precision
Implantable neurostimulator


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be diagnosed with multiple migraines per month of moderate to severe intensity;
  • Be refractory to medication;
  • Be an appropriate candidate for the surgical procedures required for this study;
  • Be willing and able to comply with all study related procedures;
  • Be capable of reading and understanding patient information materials and giving written informed consent.


  • Have onset of migraine after age 50;
  • Have a significant psychiatric disorder;
  • Have previously been treated with occipital nerve stimulation;
  • Have had an injection of botulinum toxin in the head or neck within 6 months prior to enrollment;
  • Have previously undergone destructive ganglionectomy affecting C2/C3 occipital and/or trigeminal distribution or have an occipital blockade or radio frequency procedure currently in effect;
  • Have a condition currently requiring or likely to require the use of MRI or diathermy;
  • Have an active implantable device;
  • Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00286078

United States, Colorado
Mile High Research Center
Denver, Colorado, United States, 80218
United States, Connecticut
The New England Center for Headache
Stamford, Connecticut, United States, 06902
United States, Georgia
Walton Rehabilitation Hospital
Augusta, Georgia, United States, 30901
United States, Illinois
Rush Pain Center
Chicago, Illinois, United States, 60612
Diamond Headache Clinic
Chicago, Illinois, United States, 60614
United States, Missouri
Headache Care Center
Springfield, Missouri, United States, 65807
United States, Nevada
Headache Specialists
Las Vegas, Nevada, United States, 89109
United States, New York
Albert Einstein College of Medicine - Montefiore Headache Unit
Bronx, New York, United States, 10461
United States, Oregon
The Neurological Clinic
Portland, Oregon, United States, 97210
United States, Pennsylvania
Thomas Jefferson University - Jefferson Headache
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Nashville Neuroscience Group
Nashville, Tennessee, United States, 37203
United States, Texas
Research Center
Fort Worth, Texas, United States, 76162
United States, Utah
Lifetree Clinical Research
Salt Lake City, Utah, United States, 84106
United States, Washington
Swedish Pain & Headache Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Richard Lipton, MD Albert Einstein College of Medicine of Yeshiva University
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT00286078     History of Changes
Other Study ID Numbers: EI0105 
Study First Received: February 1, 2006
Last Updated: December 3, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Boston Scientific Corporation:

Additional relevant MeSH terms:
Migraine Disorders
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases processed this record on May 24, 2016